IDEXX Laboratories (IDXX) is back in focus after first quarter 2026 results and a higher full year outlook, with revenue, earnings and management guidance now giving investors fresh numbers to assess.

Despite stronger first quarter earnings and a higher full year outlook, the stock’s 30 day share price return is down 9% and the year to date share price return is down 21%, while the 1 year total shareholder return is 2%. This suggests longer term holders have seen a modest gain even as recent momentum has cooled.

If earnings news has you reassessing opportunities in animal health and diagnostics, it may be worth widening your search to healthcare related AI plays through our stock screener, starting with 32 healthcare AI stocks

So with revenue at US$1,140.82 million, annual EPS guidance nudged higher, and the stock down sharply year to date, is IDEXX undervalued after the reset, or is the market already pricing in future growth?

Most Popular Narrative: 29.5% Undervalued

With IDEXX closing at $528.79 against a narrative fair value of $750.23, the current setup frames a wide valuation gap built on detailed growth and margin assumptions.

Rapid adoption of innovative diagnostic platforms such as inVue Dx, Catalyst Cortisol, and Cancer Dx are expanding IDEXX's addressable market and boosting recurring consumables demand, which is likely to drive sustained revenue and margin growth as new product usage ramps and menu breadth increases.

Want to see what sits behind that confidence in recurring diagnostics and margins? The narrative uses specific growth rates, rising profitability, and a premium future earnings multiple. Curious how those inputs add up to a fair value far above today’s price? The full story connects those moving parts across revenue, earnings and valuation expectations.

Result: Fair Value of $750.23 (UNDERVALUED)

However, that optimism still sits beside softer U.S. clinical visit trends and the risk that slower global diagnostic adoption or tougher price negotiations could pressure future margins.

Another Angle: Expensive on Earnings

The narrative fair value and analyst targets both lean toward upside, but the current P/E of 38.1x tells a tougher story. That is well above the US Medical Equipment industry at 24.2x and peers at 25.3x, and also above the 29.2x fair ratio the market could move toward. If sentiment cools, this valuation gap may point to more risk than reward.

Next Steps

Mixed signals or a clear message: the balance of risks and rewards is yours to judge, so move quickly from headlines to hard data with 4 key rewards and 2 important warning signs

Looking for more investment ideas?

If IDEXX has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to hunt for other stocks that could fit your approach.

• Target potential mispricings by scanning for quality companies that may trade below their estimated value through the 50 high quality undervalued stocks.
• Prioritise financial strength by filtering for companies with robust finances and low leverage using the solid balance sheet and fundamentals stocks screener (45 results).
• Spot early opportunities by reviewing a screener containing 22 high quality undiscovered gems that the broader market may not be focused on yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.